Therefore, our findings suggest that TH1579 can module the tumour microenvironment, potentially aiding in the recruitment of CD8+ T cells to the tumour site, which could underline the enhanced antitumour efficacy observed with the drug combination. This evidence concerns the gene CD8A and neoplasm.